Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Greg Verdine

Takeshi Wada

Wave Life Sciences Ltd.

Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.

Metric
Company Name	Wave Life Sciences Ltd.
Symbol	WVE
MSH ID	COM:WAVELIFESCIENCES
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	SG
Stage
Employee Count	266
Website	wavelifesciences.com
LinkedIn	wave-life-sciences
Founders

Metric
Market Cap	682.19M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	113.31M
Revenue (LTM)
Revenue (NTM)
Gross Profit	104.10M
EBITDA	-58.79M
Operating Income	-68.00M
Net Income	-57.51M
EPS	-0.54
Diluted EPS	-0.54
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94
Operating Profit Margin	-0.60
EBITDA Margin	-0.52
Net Profit Margin	-0.48
Return on Equity	21.56
Return on Assets	-0.20
Return on Capital Employed	0.61

COM:WAVELIFESCIENCES

Wave Life Sciences

Last Close

14.35

22/11 21:00

Market Cap

682.19M

Beta: -

Volume Today

455.93K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.04
P/B Ratio	-10.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	21.47
EV Multiple	-9.77

Metric
Days Sales Outstanding	29.89
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	67.93
Cash Conversion Cycle	-441.12
Asset Turnover	3.01

Metric
Operating Cash Flow	-19.43M
Free Cash Flow	-20.55M
Cash Flow to Debt	-0.60
Operating Cash Flow/Sales	-0.17
Free Cash Flow Yield	-0.04

Metric
Cash & Equivalents	200.35M
Accounts Receivable	-21.09M
Inventory
Goodwill
Debt to Capitalization	1.14
Debt to Assets	0.17
Current Ratio	1.59
Quick Ratio	1.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.12
R&D to Revenue	1.49
SG&A to Revenue	0.60